文献速递肝胆胰外科围术期管理与 ERAS

腹腔镜远端胰腺切除术优势的系统综述与Meta分析

Advantages of laparoscopic distal pancreatectomy: Systematic review and meta-analysis of randomized and matched studies.
PubMed 文献 · Surgery · 2022-12-21

腹腔镜组术后住院时间和估计失血量显著减少,手术时间相当;肿瘤学结局方面,腹腔镜组R0切除率更高、辅助治疗时间更短,1年生存有优势但3年生存无差异。

要点

  • 腹腔镜远端胰腺切除术可缩短术后住院时间和减少估计失血量。
  • 腹腔镜与开腹手术的手术时间、主要并发症、死亡率和再入院率相似。
  • 胰腺癌患者中腹腔镜手术R0切除率更高且辅助治疗更早,肿瘤学非劣效。

核心结论

  • 腹腔镜远端胰腺切除术在多数早期结局上优于开腹远端胰腺切除术。
  • 手术时间因学习曲线而趋于相等。
  • 胰腺癌患者中腹腔镜远端胰腺切除术至少不劣于开腹手术的肿瘤学结局。

研究设计与样本

  • 系统综述与Meta分析,纳入随机对照试验和倾向评分匹配研究。
  • 早期结局基于12项研究共4346例患者,肿瘤学结局基于5项研究共2430例患者。
  • 采用随机效应Meta分析和试验序贯分析。

主要发现

  • 腹腔镜远端胰腺切除术缩短术后住院时间(均数差=1.8天;P=.001)和减少估计失血量(均数差=148 mL;P=.001),试验序贯分析证实为真阳性。
  • 腹腔镜与开腹手术的手术时间相似(P=.165),试验序贯分析证实为真阴性。
  • 主要并发症、死亡率和再入院率相似,但试验序贯分析结果不确定。
  • 腹腔镜组R0切除率更高(OR=1.46;P=.001),辅助治疗时间更短(均数差4.0天;P=.003)。
  • 腹腔镜组1年生存有优势(OR=1.45;P=.001),但3年生存无差异(P=.650)。

临床怎么用

  • 腹腔镜远端胰腺切除术可作为远端胰腺切除术的优选术式,尤其注重微创优势时。
  • 对于胰腺癌患者,腹腔镜手术在肿瘤学结局上至少不劣于开腹手术,可考虑应用。
  • 需注意主要并发症、死亡率和再入院率的比较结果尚不确定,应个体化决策。

局限性

  • 纳入研究以倾向评分匹配研究为主,随机对照试验仅2项。
  • 主要并发症、死亡率和再入院率的试验序贯分析结果不确定。
  • 3年生存无差异,1年生存优势未在长期确认。
  • 肿瘤学结局仅基于5项研究,证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We sought to provide a meta-analysis and credibility assessment of available randomized controlled trials and propensity score matched studies when assessing early and oncologic outcomes of laparoscopic distal pancreatectomy compared with open distal pancreatectomy. METHODS: The MEDLINE, Scopus, Web of Science, and Cochrane databases were searched for pertinent literature up to June 2022. Random-effect meta-analyses were applied. Trial sequential analysis was applied to verify whether results were true- or false-positive or -negative findings. RESULTS: Thirteen studies were identified (2 randomized controlled trials and 11 propensity score matched studies). The early outcomes were assessed on 12 studies, including 4,346 patients. In this population, laparoscopic distal pancreatectomy decreased postoperative stay (mean difference = 1.8 days; P = .001) and estimated blood loss (mean difference = 148 mL; P = .001), and trial sequential analysis confirmed these as true-positive findings. Laparoscopic distal pancreatectomy and open distal pancreatectomy had similar operating times (P = .165), and trial sequential analysis confirmed this as a true-negative finding. Major morbidity, mortality, and readmission were similar, but results were inconclusive by trial sequential analysis. Oncologic outcomes were assessed on 5 studies, including 2,430 patients. In this population, laparoscopic distal pancreatectomy showed higher R0 resection rate (OR = 1.46; P = .001) and shorter time to adjuvant therapy (mean difference 4.0 days P = .003). A survival benefit was observed at 1 year after laparoscopic distal pancreatectomy (OR = 1.45; P = .001), which was not confirmed at 3 years (P = .650). CONCLUSION: Laparoscopic distal pancreatectomy is superior to open distal pancreatectomy for most of the early outcomes analyzed. The operating time was equalized as a result of the learning curve. Results from patients with pancreatic cancer suggest at least an oncologic noninferiority of laparoscopic distal pancreatectomy compared with open distal pancreatectomy.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Cucchetti A, Bocchino A, Crippa S, et al. Advantages of laparoscopic distal pancreatectomy: Systematic review and meta-analysis of randomized and matched studies. Surgery. 2022. PMID: 36564287. doi:10.1016/j.surg.2022.11.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。